Oliver Luxxe Assets’s Catalyst Pharmaceutical CPRX Stock Holding History

Oliver Luxxe Assets’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.56M	Sell	49,744 -46,892	-49%	-$1.38M	0.23%	123
2026 Q1	$2.39M	Buy	96,636 +19,589	+25%	+$467K	0.36%	109
2025 Q4	$1.8M	Buy	77,047 +1,646	+2%	+$36.7K	0.27%	125
2025 Q3	$1.49M	Buy	75,401 +4,161	+6%	+$85.6K	0.24%	131
2025 Q2	$1.55M	Buy	71,240 +935	+1%	+$22.1K	0.28%	117
2025 Q1	$1.7M	Sell	70,305 -32,970	-32%	-$742K	0.32%	111
2024 Q4	$2.12M	Buy	103,275 +69,250	+204%	+$1.49M	0.19%	137
2024 Q3	$676K	Buy	+34,025	New	+$631K	0.12%	148

Other funds holding CPRX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

LTAS

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

EWM

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Oliver Luxxe Assets's CPRX Position: Q2 2026 in Review

Oliver Luxxe Assets reduced its Catalyst Pharmaceutical (CPRX) stake by 49% in Q2 2026, selling an estimated $1.38M and leaving 49,744 shares worth $1.56M. The position accounts for 0.23% of the portfolio, ranked #123.

Oliver Luxxe Assets first reported a position in CPRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.39M in Q1 2026. 36 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Oliver Luxxe Assets held 49,744 shares of Catalyst Pharmaceutical worth $1.56M as of Q2 2026.
Oliver Luxxe Assets sold 46,892 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.38M.
Catalyst Pharmaceutical made up 0.23% of Oliver Luxxe Assets's portfolio in Q2 2026, its #123 holding.
Oliver Luxxe Assets first reported a position in Catalyst Pharmaceutical in Q3 2024 and has held it in 8 quarters since.
Oliver Luxxe Assets's Catalyst Pharmaceutical position peaked at $2.39M in Q1 2026.
36 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Oliver Luxxe Assets's 13F filing for Q2 2026, filed 9 Jul 2026.